AstraZeneca's 2030 $80B Revenue Goal: How Realistic?

AstraZeneca, a leading pharmaceutical company based in the UK, recently set a challenging goal: to achieve $80 billion in total revenue and introduce 20 new medicines by the end of the decade. This announcement highlights the company's commitment to enhancing operational productivity and initiating a new phase of growth. However, the feasibility of this ambitious target is under scrutiny.

Several experts have expressed skepticism regarding AstraZeneca's targets. According to Etzer Darout, a senior biotech analyst at BMO Capital Markets, the $80 billion target exceeds both his and the consensus projections. Jefferies analysts also projected a more conservative estimate, suggesting that AstraZeneca might reach $70 billion by 2030, with a general consensus around $66.8 billion.

Despite the cautious outlook, AstraZeneca has demonstrated consistent growth between 2018 and 2023, driven by successful product launches. A report from Zacks Equity Research praised the company's recent product launches, noting that nearly all new products have performed well, contributing to a portfolio that includes 12 blockbuster drugs.

Past performance, however, is not always indicative of future success. Darout emphasized that AstraZeneca's goal for a core operating margin in the mid-30% range by 2026 is achievable, provided the company continues to focus on improving productivity. Jefferies analysts, while maintaining a hold rating on AstraZeneca, pointed out that non-oncology assets are being overlooked, despite their potential for significant long-term gains.

One of the major hurdles AstraZeneca faces includes patent expirations for several key products. This year, the cancer drug Lynparza will lose its exclusivity, followed by the asthma drug Fasenra and the type 2 diabetes therapy Farxiga, which also treats heart failure and chronic kidney disease, in 2025. Darout highlighted that new product launches are critical for sustaining growth amidst these challenges.

To navigate these hurdles, AstraZeneca's CEO, Pascal Soriot, assured investors that substantial growth will come from the existing portfolio and the new medicines planned by 2030. Soriot emphasized that many of these new drugs have the potential to exceed $5 billion in peak year revenues.

Key candidates in AstraZeneca's pipeline include several mid-to-late stage development drugs. Notably, the antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd), partnered with Daiichi Sankyo, is set for a target action date for non-small cell lung cancer (NSCLC) by December 2024. This ADC is also being explored for various breast cancers. Other promising oncology assets include camizestrant for breast cancer, rilvegostomig for solid tumors and biliary tract cancer, volrustomig for NSCLC and cervical cancer, and saruparib for metastatic castration-sensitive prostate cancer.

Additionally, baxdrostat, currently in Phase III trials for chronic kidney disease and hypertension, is identified as a potential blockbuster. AstraZeneca's acquisitions, including radiopharma biotech Fusion Pharmaceuticals and cancer biotech Gracell, along with its partnership with GLP-1 developer Eccogene, could also yield significant revenue.

Darout cautioned that, like other global pharmaceutical companies, AstraZeneca must navigate competitive pressures, pricing dynamics, and regulatory risks, alongside the predictable challenge of patent expirations. The impact of these factors is less certain and more challenging to predict.

In summary, while AstraZeneca's target of $80 billion in revenue by 2030 is ambitious and faces several challenges, strategic growth from existing and new products, coupled with improved operational productivity, could potentially make this goal attainable.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!